These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11922434)

  • 1. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole.
    Robinson MW; Trudgett A; Hoey EM; Fairweather I
    Parasitology; 2002 Mar; 124(Pt 3):325-38. PubMed ID: 11922434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.
    Robinson MW; Trudgett A; Hoey EM; Fairweather I
    Parasitol Res; 2003 Sep; 91(2):117-29. PubMed ID: 12910417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
    McConville M; Brennan GP; McCoy M; Castillo R; Hernandez-Campos A; Ibarra F; Fairweather I
    Parasitology; 2006 Aug; 133(Pt 2):195-208. PubMed ID: 16650337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of a beta-tubulin gene from the liver fluke, Fasciola hepatica.
    Robinson MW; Hoey EM; Fairweather I; Dalton JP; McGonigle S; Trudgett A
    Int J Parasitol; 2001 Sep; 31(11):1264-8. PubMed ID: 11513896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasciola hepatica: tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex).
    Stitt AW; Fairweather I
    Parasitol Res; 1993; 79(7):529-36. PubMed ID: 8278333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.
    Robinson MW; Lawson J; Trudgett A; Hoey EM; Fairweather I
    Parasitol Res; 2004 Feb; 92(3):205-10. PubMed ID: 14652740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
    McConville M; Brennan GP; McCoy M; Castillo R; Hernandez-Campos A; Ibarra F; Fairweather I
    Parasitol Res; 2007 Jan; 100(2):365-77. PubMed ID: 17016729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica.
    Stitt AW; Fairweather I
    Parasitology; 1994 Jun; 108 ( Pt 5)():555-67. PubMed ID: 8052511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single amino acid substitution in isozyme GST mu in Triclabendazole resistant Fasciola hepatica (Sligo strain) can substantially influence the manifestation of anthelmintic resistance.
    Fernández V; Estein S; Ortiz P; Luchessi P; Solana V; Solana H
    Exp Parasitol; 2015 Dec; 159():274-9. PubMed ID: 26542261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasciola hepatica expresses multiple alpha- and beta-tubulin isotypes.
    Ryan LA; Hoey E; Trudgett A; Fairweather I; Fuchs M; Robinson MW; Chambers E; Timson DJ; Ryan E; Feltwell T; Ivens A; Bentley G; Johnston D
    Mol Biochem Parasitol; 2008 May; 159(1):73-8. PubMed ID: 18372053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):981-95. PubMed ID: 21442257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Exp Parasitol; 2013 Nov; 135(3):642-53. PubMed ID: 24090567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Parasitol Res; 2010 May; 106(6):1351-63. PubMed ID: 20336319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect.
    Mottier L; Alvarez L; Fairweather I; Lanusse C
    J Parasitol; 2006 Dec; 92(6):1355-60. PubMed ID: 17304820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Modelling and Molecular Docking Analysis of Fasciola hepatica β-Tubulin's Interaction Sites, with Triclabendazole, Triclabendazole Sulphoxide and Triclabendazole Sulphone.
    Olivares-Ferretti P; Beltrán JF; Salazar LA; Fonseca-Salamanca F
    Acta Parasitol; 2023 Sep; 68(3):535-547. PubMed ID: 37330945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasciola gigantica: tegumental surface alterations following treatment in vitro with the sulphoxide metabolite of triclabendazole.
    Meaney M; Fairweather I; Brennan GP; Ramasamy P; Subramanian PB
    Parasitol Res; 2002 Apr; 88(4):315-25. PubMed ID: 11999018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
    Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
    Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tegumental surface changes in juvenile Fasciola hepatica in response to treatment in vivo with triclabendazole.
    Halferty L; Brennan GP; Hanna RE; Edgar HW; Meaney MM; McConville M; Trudgett A; Hoey L; Fairweather I
    Vet Parasitol; 2008 Aug; 155(1-2):49-58. PubMed ID: 18511199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of albendazole and triclabendazole on colchicine binding in the liver fluke Fasciola hepatica.
    Fetterer RH
    J Vet Pharmacol Ther; 1986 Mar; 9(1):49-54. PubMed ID: 3701915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.